InnoPharmax (4172) Stock Overview
A specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
4172 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
InnoPharmax Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$11.00 |
| 52 Week High | NT$23.75 |
| 52 Week Low | NT$10.20 |
| Beta | 0.0077 |
| 1 Month Change | -23.88% |
| 3 Month Change | -28.10% |
| 1 Year Change | -36.42% |
| 3 Year Change | -41.02% |
| 5 Year Change | -24.40% |
| Change since IPO | -69.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4172 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -12.4% | -0.5% | 0.5% |
| 1Y | -36.4% | -11.8% | 106.7% |
Return vs Industry: 4172 underperformed the TW Pharmaceuticals industry which returned -11.8% over the past year.
Return vs Market: 4172 underperformed the TW Market which returned 106.7% over the past year.
Price Volatility
| 4172 volatility | |
|---|---|
| 4172 Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 4172's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 4172's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 34 | Weihua Hao | www.innopharmax.com |
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomustine brand; immunological agents under the Immurin brand; and Inpheno tablets for rare diseases. It also provides active pharmaceutical ingredient, including orphan drug and MRI enhancing agents.
InnoPharmax Inc. Fundamentals Summary
| 4172 fundamental statistics | |
|---|---|
| Market cap | NT$1.18b |
| Earnings (TTM) | -NT$184.40m |
| Revenue (TTM) | NT$68.99m |
Is 4172 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4172 income statement (TTM) | |
|---|---|
| Revenue | NT$68.99m |
| Cost of Revenue | NT$59.16m |
| Gross Profit | NT$9.83m |
| Other Expenses | NT$194.23m |
| Earnings | -NT$184.40m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 14.25% |
| Net Profit Margin | -267.29% |
| Debt/Equity Ratio | 2.4% |
How did 4172 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/06 20:27 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InnoPharmax Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.